Certain beta-blockers can decrease beta-adrenergic receptor number: I. Acute reduction in receptor number by tertatolol and bopindolol.
Authors:
- 1 August 1988
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 63 (2) , 273-278
Abstract
We have previously reported that a potent new beta-blocker, tertatolol, when given at therapeutic doses to healthy volunteers, rapidly reduced the number of human mononuclear leukocyte beta-receptors. In the present study, the mechanism of receptor regulation by beta-antagonists incubated with target cells in vitro was investigated. Two different cell types (human mononuclear leukocytes and S49 murine lymphoma cells) were used, and beta-adrenergic receptors were measured using either the hydrophilic ligand 3H-CGP 12177 (specific for surface receptors) or lipophilic 125I-pindolol (which measures total receptors). In a comparison between beta-blockers, tertatolol and bopindolol, but not propranolol and pindolol, were found to rapidly (1 hour at 37 degrees C) reduce the number of beta-adrenergic receptors. This was paralleled by a reduction in isoproterenol-stimulated cyclic AMP accumulation. The reduction in receptors was the same whether surface or total receptors were measured; thus, it was not due to receptor sequestration. This effect was not caused by partial agonist activity (bopindolol is a weak partial agonist); in parallel experiments, tertatolol and bopindolol, but not pindolol (potent partial agonist) and isoproterenol (full agonist), reduced beta-adrenergic receptors. Finally, this effect was not due to irreversible binding: the receptor reduction induced by the irreversible blocker bromo-acetyl-alprenolol-methane (BAAM) was stable for several hours, while the effect of tertatolol and bopindolol was slowly reversed over the same time course. We suggest that tertatolol and bopindolol have two effects on beta-adrenergic receptors: they bind competitively, and then they modify the receptors so that they are no longer available for binding by ligands or catecholamines.(ABSTRACT TRUNCATED AT 250 WORDS)Keywords
This publication has 10 references indexed in Scilit:
- ?-Adrenoceptor antagonists (non-selective as well as ? 1-selective? 2-adrenoceptor density in human lymphocytesNaunyn-Schmiedeberg's Archives of Pharmacology, 1986
- Reduction of beta-adrenergic receptors by tertatolol: An additional mechanism for beta-adrenergic blockadeClinical Pharmacology & Therapeutics, 1986
- Agonist-Induced Redistribution of 0-Adrenergic Receptors on Intact Human Mononuclear Leukocyte Redistributed Receptors Are Nonfunctional*The Journal of Clinical Endocrinology & Metabolism, 1985
- Acute and long-term antihypertensive effect of bopindolol ? A nonselective ?-adrenergic blocker with ISAEuropean Journal of Clinical Pharmacology, 1985
- Simultaneous modeling of bopindolol kinetics and dynamicsClinical Pharmacology & Therapeutics, 1984
- NL-FIT: A microcomputer program for non-linear fittingComputer Programs in Biomedicine, 1983
- Regeneration of beta-adrenergic receptors in senescent rats: a study using an irreversible binding antagonist.Proceedings of the National Academy of Sciences, 1982
- Elevation of beta-adrenergic receptor density in human lymphocytes after propranolol administration.Journal of Clinical Investigation, 1980
- Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic propertiesAmerican Heart Journal, 1979
- THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONSAnnals of the New York Academy of Sciences, 1949